The suppressive effect of dabrafenib, a therapeutic agent for metastatic melanoma, in IgE-mediated allergic inflammation

Choi, Young‐Ae; Lee, So‐Young; Choi, Jin Kyeong; Kang, Byeong‐Cheol; Kim, Min-Jong; Dhakal, Hima; Kwon, Taeg Kyu; Khang, Dongwoo; Kim, Sang-Hyun

doi:10.1016/j.intimp.2020.106398

Cited by 4 publications

(17 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mast cells release various mediators after cross-linking of the IgE receptors on their surface and can induce an immediate allergic reaction. The procedure of degranulation in mast cells comprises fusing of the membrane of the granules, including biogenic amines such as histamine, lysosomal enzymes such as β-hexosaminidase, lipid mediators, and cytokines [ 23 ]. Experimentally, mast cell degranulation can be activated via FcεRI by using anti-IgE [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

“…The IgE-mediated passive cutaneous anaphylaxis model was established as described previously [ 23 ]. The ear skin of the mouse ( n = 6/group) was sensitized by intradermal injection of anti-DNP-IgE (0.5 µg/site) using an insulin syringe.…”

Section: Methodsmentioning

confidence: 99%

“…Cell culture and RNA isolation were performed as described previously [ 23 ]. The RBL-2H3 cells were stimulated with DNP-BSA for 1 h and harvested.…”

Section: Methodsmentioning

confidence: 99%

“…Western blotting was performed as described previously [ 23 ]. Nuclear and Cytoplasmic samples of cells were performed using a nuclear and cytoplasmic extraction reagents kit (Thermo fisher, Waltham, MA, USA) according to the manufacturer’s protocols.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Extract of Boehmeria nivea Suppresses Mast Cell-Mediated Allergic Inflammation by Inhibiting Mitogen-Activated Protein Kinase and Nuclear Factor-κB

Lim

Lee

et al. 2020

Molecules

Self Cite

View full text Add to dashboard Cite

Mast cells are effector cells that initiate allergic inflammatory immune responses by inducing inflammatory mediators. Boehmeria nivea (Linn.) Gaudich is a natural herb in the nettle family Urticaceae that possesses numerous pharmacological properties. Despite the various pharmacological benefits of Boehmeria nivea, its effects on allergic inflammation have not yet been determined. Here, we investigated the effect of the ethanol extract of Boehmeria nivea (BNE) on degranulation rat basophilic leukemia (RBL)-2H3 mast cells stimulated with anti-dinitrophenyl (anti-DNP) and bovine serum albumin (BSA) during immunoglobulin E (IgE)-mediated allergic immune response. The results showed inhibition of the release of β-hexosaminidase and histamine from the cells. BNE suppressed pro-inflammatory cytokines (Tumor necrosis factor (TNF)-α, Interleukin (IL)-1β, and IL-6) and reduced T helper (Th)2 cytokine IL-4 expression and/or secretion correlated with the downregulation of p38, extracellular signal-regulated kinases (ERK) mitogen-activated protein kinase (MAPK), and nuclear factor-κB (NF-κB) signaling pathways in treated RBL-2H3 mast cells. In passive cutaneous anaphylaxis, treatment with BNE during IgE-mediated local allergic reaction triggered a reduction in mouse ear pigmentation and thickness. Taken together, these results indicated that BNE suppressed mast cell-mediated inflammation, suggesting that BNE might be a candidate for the treatment of various allergic disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…Cell culture and RNA isolation were performed as described previously [ 23 ]. The RBL-2H3 cells were stimulated with DNP-BSA for 1 h and harvested.…”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Extract of Boehmeria nivea Suppresses Mast Cell-Mediated Allergic Inflammation by Inhibiting Mitogen-Activated Protein Kinase and Nuclear Factor-κB

Lim

Lee

et al. 2020

Molecules

Self Cite

View full text Add to dashboard Cite

show abstract

“…Emerging evidence suggests that gut microbial metabolites, including SCFAs, inosine, urolithin A, urolithin B, and bacteriocins, possess immunomodulatory and anticancer properties. Previous studies have demonstrated their potential therapeutic applications in various cancer types, including lymphoma [9]. However, the precise mechanisms by which the gut microbiota and its metabolites influence lymphoma risk and progression are still being elucidated, necessitating further research to identify therapeutic targets.…”

Section: Introductionmentioning

confidence: 99%

The Gut Connection: Exploring the Possibility of Implementing Gut Microbial Metabolites in Lymphoma Treatment

Al-Khazaleh,

Chang,

Münch

et al. 2024

Cancers

View full text Add to dashboard Cite

Recent research has implicated the gut microbiota in the development of lymphoma. Dysbiosis of the gut microbial community can disrupt the production of gut microbial metabolites, thereby impacting host physiology and potentially contributing to lymphoma. Dysbiosis-driven release of gut microbial metabolites such as lipopolysaccharides can promote chronic inflammation, potentially elevating the risk of lymphoma. In contrast, gut microbial metabolites, such as short-chain fatty acids, have shown promise in preclinical studies by promoting regulatory T-cell function, suppressing inflammation, and potentially preventing lymphoma. Another metabolite, urolithin A, exhibited immunomodulatory and antiproliferative properties against lymphoma cell lines in vitro. While research on the role of gut microbial metabolites in lymphoma is limited, this article emphasizes the need to comprehend their significance, including therapeutic applications, molecular mechanisms of action, and interactions with standard chemotherapies. The article also suggests promising directions for future research in this emerging field of connection between lymphoma and gut microbiome.

show abstract

The Gut Connection: Exploring The Possibility Of Implementing Gut Microbial Metabolites in Lymphoma Treatment

Al-Khazaleh,

Chang,

Münch

et al. 2024

Preprint

View full text Add to dashboard Cite

Recent research has implicated the gut microbiota in the development of lymphoma. Dysbiosis of the gut microbial community can disrupt the production of gut microbial metabolites, thereby impacting host physiology and potentially contributing to lymphoma. Dysbiosis-driven release of gut microbial metabolites such as lipopolysaccharides can promote chronic inflammation, potentially elevating the risk of lymphoma. In contrast, gut microbial metabolites, such as short-chain fatty acids, have shown promise in preclinical studies by promoting regulatory T-cell function, suppressing inflammation, and preventing lymphoma. Another metabolite, urolithin A, exhibited immunomodulatory and antiproliferative properties against lymphoma cell lines in vitro. While research on the role of gut microbial metabolites in lymphoma is limited, this article emphasizes the need to comprehend their significance, including therapeutic applications, molecular mechanisms of action, and interactions with standard chemotherapies. The article also suggests promising directions for future research in this emerging lymphoma and gut microbiome investigation field.

show abstract

The suppressive effect of dabrafenib, a therapeutic agent for metastatic melanoma, in IgE-mediated allergic inflammation

Cited by 4 publications

References 46 publications

Extract of Boehmeria nivea Suppresses Mast Cell-Mediated Allergic Inflammation by Inhibiting Mitogen-Activated Protein Kinase and Nuclear Factor-κB

Extract of Boehmeria nivea Suppresses Mast Cell-Mediated Allergic Inflammation by Inhibiting Mitogen-Activated Protein Kinase and Nuclear Factor-κB

The Gut Connection: Exploring the Possibility of Implementing Gut Microbial Metabolites in Lymphoma Treatment

The Gut Connection: Exploring The Possibility Of Implementing Gut Microbial Metabolites in Lymphoma Treatment

Contact Info

Product

Resources

About